IGC Pharma, Inc. (IGC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45408X3089
IGC Pharma, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 1.27 m USD | 1.19 m USD |
| Gross profit | 619,000.00 USD | 352,000.00 USD |
| Operating income | -7.45 m USD | -10.20 m USD |
| EBIT | -7.12 m USD | – |
| Net income | -7.12 m USD | -6.55 m USD |
| Diluted EPS – continuing operations | -0.09 USD | – |
Full history since 2006, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About IGC Pharma, Inc.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
More stocks
- Netcapital Inc. (NCPL)
- Dominari Holdings Inc. (DOMH)
- BIOLARGO, INC. (BLGO)
- LIVE VENTURES Inc (LIVE)
- SPRUCE POWER HOLDING CORP (SPRU)
- DESTINATION XL GROUP, INC. (DXLG)
- Retrieve Medical Holdings, Inc. (RMHI)
- Mono Next Public Company Limited (MONO.BK)
- GEE Group Inc. (JOB)
- AMERICAN VANGUARD CORP (AVD)
- MARIMED INC. (MRMD)
- Veritone, Inc. (VERI)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.